8LY Stock Overview
A pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
OncoZenge AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.33 |
| 52 Week High | SEK 0.99 |
| 52 Week Low | SEK 0.23 |
| Beta | 1.16 |
| 11 Month Change | -63.00% |
| 3 Month Change | -40.22% |
| 1 Year Change | 26.86% |
| 33 Year Change | -66.83% |
| 5 Year Change | n/a |
| Change since IPO | -73.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8LY | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -52.8% | -1.2% | -0.02% |
| 1Y | 26.9% | -20.1% | 8.2% |
Return vs Industry: 8LY exceeded the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: 8LY exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| 8LY volatility | |
|---|---|
| 8LY Average Weekly Movement | 20.3% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8LY's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8LY's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 2 | Stian Kildal | oncozenge.com |
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.
OncoZenge AB (publ) Fundamentals Summary
| 8LY fundamental statistics | |
|---|---|
| Market cap | €3.56m |
| Earnings (TTM) | -€813.67k |
| Revenue (TTM) | €260.87 |
Over9,999x
P/S Ratio-4.4x
P/E RatioIs 8LY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8LY income statement (TTM) | |
|---|---|
| Revenue | SEK 3.00k |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 3.00k |
| Other Expenses | SEK 9.36m |
| Earnings | -SEK 9.36m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.80 |
| Gross Margin | 100.00% |
| Net Profit Margin | -311,900.00% |
| Debt/Equity Ratio | 0% |
How did 8LY perform over the long term?
See historical performance and comparison